Keywords: gilead, acquire, cv, thera, 4b, marketletter, going
Gilead to acquire CV Thera for $1.4B
Article | 16 March 2009
As the Marketletter was going to press, the USA's Gilead Sciences announced that it was to acquire CV Therapeutics for $1.4 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
